Mutation Clinical Trials

5 recruiting

Mutation Trials at a Glance

281 actively recruiting trials for mutation are listed on ClinicalTrialsFinder across 6 cities in 44 countries. The largest study group is Phase 2 with 105 trials, with the heaviest enrollment activity in Boston, New York, and Houston. Lead sponsors running mutation studies include M.D. Anderson Cancer Center, The First Affiliated Hospital of Soochow University, and Dana-Farber Cancer Institute.

Browse mutation trials by phase

Treatments under study

About Mutation Clinical Trials

Looking for clinical trials for Mutation? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Mutation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Mutation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 281 trials

Recruiting

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

Familial CancerMesotheliomaBRCA1-Associated Protein-1 (BAP1) Mutations+1 more
National Cancer Institute (NCI)800 enrolled1 locationNCT04431024
Recruiting

Vascular Disease Discovery Protocol

Vascular DysfunctionGenetic PredispositionGenetic Mutations
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT03538639
Recruiting
Phase 2

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

Partial LipodystrophyInsulin Receptor Mutation
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)25 enrolled1 locationNCT05470504
Recruiting
Phase 1

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Atopic DermatitisLupusHyper IgE Syndrome From STAT3 Mutation+2 more
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT07262983
Recruiting

Clinical and Genetic Studies of Li-Fraumeni Syndrome

NeoplasmsLi-Fraumeni SyndromeTp53 Mutations
National Cancer Institute (NCI)5,000 enrolled2 locationsNCT01443468
Recruiting
Phase 1Phase 2

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)

Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
Precision BioSciences, Inc.18 enrolled1 locationNCT07429240
Recruiting

TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

NSCLC Stage IVPD-L1 Gene MutationAtezolizumab+1 more
Antalya Training and Research Hospital150 enrolled25 locationsNCT07279402
Recruiting

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Acute Myeloid LeukemiaMyelodysplastic SyndromesGermline Mutation
National Cancer Institute (NCI)510 enrolled1 locationNCT07019155
Recruiting
Phase 2

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

BRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more
University of California, San Francisco96 enrolled5 locationsNCT07110246
Recruiting
Phase 2

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc90 enrolled35 locationsNCT06995677
Recruiting
Phase 2

Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

GIST - Gastrointestinal Stromal TumorKIT Gene Mutation
Jian Li100 enrolled1 locationNCT07559864
Recruiting
Phase 2

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Solid TumorWilms TumorRhabdoid Tumor+4 more
Memorial Sloan Kettering Cancer Center45 enrolled16 locationsNCT05985161
Recruiting
Phase 2

Ivosidenib as Post-HSCT Maintenance for AML

Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled4 locationsNCT06707493
Recruiting
Not Applicable

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Groupe Francais De Pneumo-Cancerologie30 enrolled18 locationsNCT06247826
Recruiting

A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT

Acute LeukemiaMenin InhibitorsPost Hematopoietic Stem Cell Transplantation+4 more
The First Affiliated Hospital of Soochow University20 enrolled1 locationNCT07559695
Recruiting

World Data on Ambroxol for Patients With GD and GBA Related PD

Gaucher DiseaseParkinson DiseaseGBA Gene Mutation
Shaare Zedek Medical Center300 enrolled3 locationsNCT04388969
Recruiting
Not Applicable

Early Diagnosis of High-grade Serous Epithelial Ovarian Cancer Through the Analysis of DNA Derived From Pap Test Smear.

Germline Mutations
Fondazione Policlinico Universitario Agostino Gemelli IRCCS260 enrolled1 locationNCT07556562
Recruiting
Not Applicable

The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care

Breast CancerHead and Neck CancerGastrointestinal Cancer+2 more
University of Chicago860 enrolled1 locationNCT04541381
Recruiting
Not Applicable

Videocapsule Endoscopy in Lynch Syndrome

Lynch SyndromeLynch Syndrome ILynch Syndrome II+4 more
San Raffaele University100 enrolled1 locationNCT05704010
Recruiting

Lynch Syndrome X-Talk of Enteral Mucosa With Immune System

Hereditary Cancer SyndromeHereditary CancerLynch Syndrome+19 more
San Raffaele University300 enrolled5 locationsNCT06708429